Skip to main content

Dominion Diagnostics Licenses Rights to LifeGen Genetic Test Technology

NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.

The firms are currently collaborating on a study to validate LifeGen's test, which determines a patient's Genetic Addiction Risk Score. The test is being compared in the study to the Addiction Severity Index marketed by Inflexxion.

The LifeGen test includes a panel of genes primarily involved in brain reward circuitry, said North Kingston, RI-based Dominion Diagnostics. The firms, however, didn't provide specific details of which genes are in the panel, but they noted that a subset of the population "carries the DRD2 Type A1 receptor gene, which induces low dopamine brain function that results in the propensity for addictive cravings."

Further details of the alliance and licensing agreement were not disclosed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.